Genenesce Backs Off After Clinical Approval: A Biotech Red Flag

A Company That Won the Permit But Lost Its Nerve

Genenesce received Korea’s medical-device regulator approval for its COVID-19 drug candidate in October 2021. Seven months later, it had enrolled only 109 patients and stopped asking for more. By February 2023, it formally asked its contract research organization to pause all overseas trials. By May, it sent a letter calling the entire program a “provisional suspension” — domestic and international.

The pattern is unusual enough to matter beyond one company. A drug sponsor does not back away from a completed regulatory gate without a reason. When that reason is unprofitability, questionable data, and a criminal conviction hanging over the founder, the signal reaches every biotech investor watching Korea.

From Shingles Drug to Pandemic Pivot

Professor Kang founded Genenesce in 2016 to develop ES16001, an extract from a plant known as dampalsu, as a treatment for shingles. The company completed a Phase 1 trial in 2020. When the pandemic accelerated, the same molecule was repurposed as a COVID therapy.

The shift was fast. Genenesce contracted J University researchers to measure antiviral activity and received a report stating only “some antiviral effect.” No animal study confirmed benefit. No patient data proved it. Still, the company moved to a Phase 2 trial in India with 60 patients and declared efficacy established.

Korea’s Ministry of Food and Drug Safety rejected that claim. It asked Genenesce to reapply from Phase 2 and supply hamster study data. That data would become central to what happened next.

The Hamster Report and the Deleted Pages

In June 2021, J University researchers tested ES16001 on hamsters infected with COVID-19. The results showed no improvement in body weight, temperature, viral load, or lung lesions. Genenesce asked for a higher dose. One of five hamsters died. Researchers also observed drug reflux and vomiting.

Genenesce then sent the university a request to delete those findings from the final report. It worked. The deleted version was submitted to the patent office and used to secure a COVID drug patent in January 2021. The court later described portions of that filing as containing false content or omitted required disclosures.

Professor Kang has pushed back publicly, arguing that deaths not clearly caused by the drug are routinely excluded from reports. The legal record, however, does not support the conclusion that the hamster data was handled properly.

The Numbers Tell the Real Story

The contractual record makes the timeline visible. In January 2021, Genenesce signed a 9.9 billion won contract with CRO K for trial design and management. By June 2021, that figure rose to 12 billion won. These were preparation costs for an application that would be submitted in September and approved in October.

After approval, the plan changed:

• January 2022: Contract revised to remove Phase 3, limiting scope to Phase 2 with a target of 424 patients.
• May 2022: First patient enrolled — seven months after approval.
• December 2022: 109 patients recruited; only 100 entered the trial. Genenesce requested a halt on recruitment.
• February 2023: Genenesce asked K to stop overseas trials, citing funding issues and an ongoing prosecution.
• May 2023: Formal notice of provisional suspension for all trials.

K filed a claim for approximately 28.7 billion won in unpaid fees. In September 2024, the first-instance court ordered Genenesce to pay roughly 4.58 billion won. The appeal is ongoing.

What the Court Has Already Said

A separate criminal case produced a first-instance sentence of three years in prison with a five-year suspension for Professor Kang on charges including violations of the Capital Markets Act. The judgment referenced misleading disclosures tied to the company’s clinical claims.

These are first-instance rulings. Appeals remain possible. But the factual record they contain is accessible and relevant to anyone assessing whether Genenesce’s pipeline carries investment-grade credibility.

Why This Matters Beyond Korea

Korea has spent years positioning itself as a hub for clinical research and biotech investment. Government policy, tax incentives, and a fast-track regulatory pathway are designed to attract sponsors and CROs. A company that secures approval and then quietly contracts its own program sends a conflicting message.

Investors who backed Genenesce on the assumption that regulatory approval signals therapeutic viability face a re-evaluation. The approval was conditional — the regulator explicitly refused to accept the Indian Phase 2 data as sufficient. The subsequent hamster report was altered. The patent filing contained material omissions. The company then reduced its trial scope and paused enrollment.

CROs face the same recalibration. K’s lawsuit is not isolated. When sponsors treat regulatory milestones as exits rather than starting points, contract partners absorb the risk. The 28.7 billion won claim reflects costs already incurred for work that will never generate revenue.

The Bigger Signal

Biotech valuations depend on pipelines. Pipelines depend on data. Data depends on sponsors who complete what they start. When a company wins approval and then abandons the program, the market loses confidence in the pipeline metric — and in the sponsors who produce it.

The Genenesce case is not yet final. The appeal courts will review both the criminal and civil matters. But the structural question remains: how much weight should investors give to a regulatory approval obtained through a process that allowed major data revisions and still produced a program that collapsed within two years?

The answer will shape pricing for Korean biotech deals. If the market discounts approvals from sponsors with contested records, deal spreads widen and capital migrates to jurisdictions with cleaner precedents. If the market treats this as an outlier, the incentive to enforce data integrity weakens.

Who Wins, Who Loses

Sponsors with clean data and transparent trial conduct win. CROs that refuse to edit negative findings win. Regulators that insist on full reporting win — eventually, even when enforcement is slow.

Sponsors who treat approval as a finish line lose. Investors who conflate regulatory speed with therapeutic promise lose. Markets that undervalue data integrity lose hardest.

Genenesce’s trajectory — from shingles candidate to COVID pivot, from approved trial to suspended enrollment — is now part of the public record. The question for biotech investors is whether they will read it as a single failure or as a warning about how quickly a permit can outpace a program.